Ozan Yazıcı
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers 11
- HER2/EGFR in Cancer Research 9
- Pancreatic and Hepatic Oncology Research 8
- Inflammatory Biomarkers in Disease Prognosis 8
-
- Breast Cancer Treatment Studies 8
-
- Gastric Cancer Management and Outcomes 11
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 8
- Colorectal and Anal Carcinomas 7
- Co-authors
- Nuriye ÖzdemirNurullah ZenginMehmet Alı Nahıt ŞendurYakup BozkayaGökmen Umut ErdemSercan AksoyNebi Serkan DemirciAhmet Özet
- Journals
- Journal of Clinical Oncology (8 papers)Current Medical Research and Opinion (7 papers)Annals of Oncology (6 papers)
- Partner nations
- TürkiyeIndiaUnited Kingdom
In The Last Decade
Ozan Yazıcı
95 papers receiving 668 citations
Peers
Comparison fields: 5 of 99
- Oncology 328
- Cancer Research 80
- Pulmonary and Respiratory Medicine 172
- Gastroenterology 23
- Pathology and Forensic Medicine 60
Countries citing papers authored by Ozan Yazıcı
This map shows the geographic impact of Ozan Yazıcı's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ozan Yazıcı with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ozan Yazıcı more than expected).
Fields of papers citing papers by Ozan Yazıcı
This network shows the impact of papers produced by Ozan Yazıcı. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ozan Yazıcı. The network helps show where Ozan Yazıcı may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ozan Yazıcı, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 2 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 0 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 0 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 3 | |
| 11 | 2022 | 10 | |
| 12 | 2022 | 10 | |
| 13 | 2021 | 13 | |
| 14 | Meme Kanserinde Epidemiyolojik Veriler, Risk Faktörleri, Risk Azaltıcı Yaklaşımlar | 2018 | 1 |
| 15 | Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer. | 2016 | 9 |
| 16 | 2015 | 27 | |
| 17 | Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients. | 2014 | 3 |
| 18 | 2014 | 4 | |
| 19 | 2014 | 16 | |
| 20 | 2014 | 5 |
About Ozan Yazıcı
Ozan Yazıcı is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 109 papers that have together received 674 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (11 papers), Cancer Immunotherapy and Biomarkers (11 papers), HER2/EGFR in Cancer Research (9 papers), Pancreatic and Hepatic Oncology Research (8 papers), Breast Cancer Treatment Studies (8 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers), Inflammatory Biomarkers in Disease Prognosis (8 papers) and Colorectal and Anal Carcinomas (7 papers). The work is most often cited by research in Oncology (328 citations), Cancer Research (80 citations) and Pulmonary and Respiratory Medicine (172 citations). Ozan Yazıcı has collaborated with scholars based in Türkiye, India and United Kingdom. Frequent co-authors include Nuriye Özdemir, Nurullah Zengin, Mehmet Alı Nahıt Şendur, Yakup Bozkaya, Gökmen Umut Erdem, Sercan Aksoy, Nuriye Özdemir, Nebi Serkan Demirci, Ahmet Özet and Sibel Çakır. Their work appears in journals such as Journal of Clinical Oncology, Current Medical Research and Opinion, Annals of Oncology, BMC Cancer and Journal of Clinical Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.